Abbott may have to share the remains of the
TURKEY in Thanksgiving....but why worry, if
BII does'nt get taken over by abbott their $!!mil dollar loan is convertible at $4 by which time the value of the loan may be $16 or more.
I hope that from tomorrow, with THANKSGIVING over, we will be seeing
the
share price start to REALLY move...........
The share has several key components that all of us should be aware of,
as this price is extremely FALSE and undervalued.......
Let's examine why?
1.Last Year, Johnson & Johnson and BII talked all the way to œ14 without
striking a deal, based on JnJ's interest then in BII's UNAPPROVED stent
product(holds open arteries in surgery...only two other makers in the
world).
2.Merrill Lynch six months ago issued a strong buy with a price target
of œ2.60,
updating it in the light of recent events to nearer œ6.
3.Boston Scientific and Abbott start getting interested.
Pause for a moment and take this on board!!
The CORE of their interest, all three, is that they could'nt give a toss
for
BII's product outside the USA, they were-are, only interested in the
product,
and possibly the company, in the context of a Federal Drug
Administration
Agency approved product for the USA markets.
That is the CENTRAL issue. Read on!
4.Abbott, sensing that BII are near to FAST TRACKING the stents through
the
FDA, give BII an UNSECURED loan of œ7 mil...to buy out the 40%
of product rights they dont own from another American partner in the
product.
Well, they did get a bit of security, i.e. the right to convert the loan
at "wait for it"
yep, you got it...œ2.60.
5. The share price starts to go mad, and all the Newspapers, and I mean
ALL,
reccommend it even naming prices, from œ4.90 thru œ6 within
days......Did'nt
happen yet.
6. Nomura issue a BUY rating
7. Killinick, followed by others........
8. Saloman Smith Barney issue a BUY yesterday........price went down.
WHY?????????
To let the INSTITUTIONS in before the BIG DAY!!!!!!
It never ceases to happen....you and me dont count.....before the IT
happens
a stock's price always goes back 20% or so from recent highs to give the
institutions their fill....THAT IS NOT A STATEMENT OF FACT,SIMPLY MY
OPINION....
What is the IT>>>>>>>>>>>>>>>>>>>
Tjhis share is all about STENTS, andnothing to do with analysts
reccommendations,
and nothing to do with the very impressive FINANCIALS last week....
IT is all about........FEDERAL DRUG ADMINISTRATION AGENCY
approval!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
If that happens, we will see the PREMPTIVE strike made by ABBOTT,
with their œ7 million, convertibles, turned into a dogfight between J &
J,
Boston (been smarting for two years at failing to get BII, just read
shareholder comments on YAHOO 2 months ago...BSX), and if ABBOTT
dont get the deal ultimately, they have œ7 million pounds convertible at
œ2.60
which will yield enough profit to cover their anticipated share losses
for 1999.
Target..œ6 plus certainly.....Sell half your holding and hold for
more.....
Chances of Fda approval....................10/1 on!!!
DONT SELL AT THESE PRICES!!!!!!!!!!
The purpose of the ADMIRE list is to generate interest and discussion in
equities. It is not in any way a placing memorandum or offer document or
a
treaty or invitation to purchase or acquire equities. Members should
always obtain their own independent financial advice.
The information in the ADMIRE list is confidential and proprietary and
is
intended only for the persons to whom it is transmitted. Receipt or
possession of information does not convey any rights to disclose its
contents in whole or in part to any third party.
The ADMIRE list does not constitute an offer to sell or purchase any
securities. Opinions expressed within the ADMIRE list are personal
opinions
of its members and are NOT to be relied upon as accurate. It must be
understood that projections and predictions about a company's future
performance are necessarily subject to a high degree of uncertainty, and
no
warranty is expressed or implied herein.
Any persons considering making an investment on the basis of information
contained in the ADMIRE list are urged to make their own enquiries and
to
form their own opinions on the company and its prospects. And if
necessary, to seek professional advice.
Investment in certain quoted companies involves a high degree of risk.
An
investment should only be considered by those persons who could sustain
a
loss on their investment. |
